| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.85 [0.76, 0.95] | | < 1 | | 0% | 3 studies (3/-) | 99.8 % | low | not evaluable | high | crucial | - |
| PFS (extension) | 0.80 [0.69, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.79 [0.71, 0.87] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| DOR | 0.78 [0.63, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.83 [0.23, 3.05] | | > 1 | | 98% | 3 studies (3/-) | 39.1 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.87 [0.76, 4.56] | | < 1 | | 8% | 2 studies (2/-) | 8.6 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.29 [1.05, 1.59] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.94 [0.48, 7.81] | | < 1 | | 0% | 1 study (1/-) | 17.6 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.24 [1.46, 3.43] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.33 [0.96, 1.84] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.82 [1.16, 2.87] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.58 [0.99, 2.52] | | < 1 | | 0% | 2 studies (2/-) | 2.8 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.28 [0.89, 1.82] | | < 1 | | 66% | 2 studies (2/-) | 8.9 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 2.55 [0.41, 15.93] | | < 1 | | 0% | 2 studies (2/-) | 15.9 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.83 [0.20, 3.51] | | < 1 | | 0% | 1 study (1/-) | 59.9 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.15 [0.77, 1.71] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.00 [0.09, 44.58] | | < 1 | | 0% | 1 study (1/-) | 33.2 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.15 [0.47, 2.82] | | < 1 | | 0% | 1 study (1/-) | 38.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.00 [0.03, 29.90] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.00 [0.09, 44.58] | | < 1 | | 0% | 1 study (1/-) | 33.2 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.29 [0.67, 2.48] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.83 [0.58, 1.19] | | < 1 | | 0% | 1 study (1/-) | 84.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.13 [0.34, 3.69] | | < 1 | | 0% | 1 study (1/-) | 42.2 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.99 [0.73, 1.36] | | < 1 | | 0% | 1 study (1/-) | 52.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 6.05 [0.34, 108.78] | | < 1 | | 0% | 1 study (1/-) | 11.3 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 10.16 [0.59, 174.64] | | < 1 | | 0% | 1 study (1/-) | 5.7 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.04 [0.48, 2.24] | | < 1 | | 0% | 1 study (1/-) | 46.0 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.72 [0.16, 3.24] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 2.92 [0.59, 14.54] | | < 1 | | 0% | 1 study (1/-) | 9.6 % | NA | not evaluable | | non important | - |
| Cardiomyopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 2.91 [0.30, 28.05] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.85 [0.33, 2.24] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.96 [0.19, 4.80] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.10 [0.54, 2.22] | | < 1 | | 0% | 1 study (1/-) | 39.9 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.48 [0.09, 2.63] | | < 1 | | 0% | 1 study (1/-) | 80.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.35 [0.11, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.96 [0.38, 2.45] | | < 1 | | 0% | 1 study (1/-) | 53.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.55 [0.50, 4.79] | | < 1 | | 0% | 1 study (1/-) | 22.2 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.55 [0.50, 4.79] | | < 1 | | 0% | 1 study (1/-) | 22.2 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.94 [0.35, 10.63] | | < 1 | | 0% | 1 study (1/-) | 22.4 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 0.64 [0.11, 3.86] | | < 1 | | 0% | 1 study (1/-) | 68.5 % | NA | not evaluable | | non important | - |
| Myopathy AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.60 [0.19, 1.84] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.02 [0.63, 1.64] | | < 1 | | 0% | 1 study (1/-) | 46.8 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Pericarditis AE (grade 3-4) | 1.93 [0.06, 57.72] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 2.07 [1.03, 4.17] | | < 1 | | 0% | 1 study (1/-) | 2.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.16 [0.02, 1.33] | | < 1 | | 0% | 1 study (1/-) | 95.4 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 3.27 [0.89, 11.95] | | < 1 | | 0% | 1 study (1/-) | 3.7 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 3.87 [0.17, 86.09] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.96 [0.02, 48.73] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 5.82 [0.29, 116.53] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.96 [0.14, 6.88] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 0.16 [0.01, 3.20] | | < 1 | | 0% | 1 study (1/-) | 88.2 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.96 [0.06, 15.47] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.93 [0.17, 21.40] | | < 1 | | 0% | 1 study (1/-) | 29.7 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.77 [0.21, 2.89] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 5.82 [0.29, 116.53] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
